vs
Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and cbdMD, Inc. (YCBD). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $5.0M, roughly 1.8× cbdMD, Inc.). cbdMD, Inc. runs the higher net margin — -5.6% vs -60.3%, a 54.7% gap on every dollar of revenue. On growth, cbdMD, Inc. posted the faster year-over-year revenue change (-1.9% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-977.3K). Over the past eight quarters, cbdMD, Inc.'s revenue compounded faster (7.1% CAGR vs -6.7%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
cbdMD, Inc. is a U.S.-based consumer wellness company that manufactures and distributes hemp-derived CBD products, including tinctures, topicals, gummies, pet care items, and bath products. All offerings undergo third-party quality testing, and are sold via e-commerce platforms, brick-and-mortar retail stores, and wellness partner channels primarily across the United States.
PLX vs YCBD — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $5.0M |
| Net Profit | $-5.5M | $-283.1K |
| Gross Margin | 49.4% | 59.8% |
| Operating Margin | -51.1% | -5.7% |
| Net Margin | -60.3% | -5.6% |
| Revenue YoY | -49.9% | -1.9% |
| Net Profit YoY | -184.8% | -1975.7% |
| EPS (diluted) | $-0.06 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | $5.0M | ||
| Q3 25 | $17.9M | $4.7M | ||
| Q2 25 | $15.7M | $4.6M | ||
| Q1 25 | $10.1M | $4.7M | ||
| Q4 24 | $18.2M | $5.1M | ||
| Q3 24 | $18.0M | $4.6M | ||
| Q2 24 | $13.5M | $5.2M | ||
| Q1 24 | — | $4.4M |
| Q4 25 | $-5.5M | $-283.1K | ||
| Q3 25 | $2.4M | $-680.0K | ||
| Q2 25 | $164.0K | $-895.3K | ||
| Q1 25 | $-3.6M | $-480.8K | ||
| Q4 24 | $6.5M | $15.1K | ||
| Q3 24 | $3.2M | $-152.8K | ||
| Q2 24 | $-2.2M | $459.7K | ||
| Q1 24 | — | $-3.0M |
| Q4 25 | 49.4% | 59.8% | ||
| Q3 25 | 53.4% | 58.8% | ||
| Q2 25 | 62.5% | 61.5% | ||
| Q1 25 | 19.1% | 62.3% | ||
| Q4 24 | 78.7% | 66.5% | ||
| Q3 24 | 53.4% | 53.9% | ||
| Q2 24 | 29.8% | 65.8% | ||
| Q1 24 | — | 59.0% |
| Q4 25 | -51.1% | -5.7% | ||
| Q3 25 | 11.9% | -14.5% | ||
| Q2 25 | 7.5% | -19.6% | ||
| Q1 25 | -41.0% | -10.2% | ||
| Q4 24 | 39.6% | -1.7% | ||
| Q3 24 | 22.2% | -6.9% | ||
| Q2 24 | -18.0% | -7.4% | ||
| Q1 24 | — | -35.4% |
| Q4 25 | -60.3% | -5.6% | ||
| Q3 25 | 13.2% | -14.4% | ||
| Q2 25 | 1.0% | -19.4% | ||
| Q1 25 | -35.8% | -10.1% | ||
| Q4 24 | 35.6% | 0.3% | ||
| Q3 24 | 18.0% | -3.4% | ||
| Q2 24 | -16.4% | 8.9% | ||
| Q1 24 | — | -68.8% |
| Q4 25 | $-0.06 | — | ||
| Q3 25 | $0.03 | — | ||
| Q2 25 | $0.00 | — | ||
| Q1 25 | $-0.05 | — | ||
| Q4 24 | $0.10 | — | ||
| Q3 24 | $0.03 | — | ||
| Q2 24 | $-0.03 | $-0.15 | ||
| Q1 24 | — | $-1.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | $3.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.2M | $9.0M |
| Total Assets | $82.3M | $11.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.7M | $3.4M | ||
| Q3 25 | $13.6M | $2.3M | ||
| Q2 25 | $17.9M | $1.1M | ||
| Q1 25 | $19.5M | $1.8M | ||
| Q4 24 | $19.8M | $2.0M | ||
| Q3 24 | $27.4M | $2.5M | ||
| Q2 24 | $23.4M | $2.4M | ||
| Q1 24 | — | $2.1M |
| Q4 25 | $48.2M | $9.0M | ||
| Q3 25 | $52.9M | $7.2M | ||
| Q2 25 | $49.9M | $6.1M | ||
| Q1 25 | $45.2M | $665.8K | ||
| Q4 24 | $43.2M | $1.8M | ||
| Q3 24 | $32.4M | $2.0M | ||
| Q2 24 | $28.6M | $3.0M | ||
| Q1 24 | — | $3.1M |
| Q4 25 | $82.3M | $11.8M | ||
| Q3 25 | $82.3M | $10.4M | ||
| Q2 25 | $78.5M | $9.9M | ||
| Q1 25 | $73.9M | $10.9M | ||
| Q4 24 | $73.4M | $11.5M | ||
| Q3 24 | $61.6M | $10.6M | ||
| Q2 24 | $91.5M | $13.8M | ||
| Q1 24 | — | $14.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $-812.5K |
| Free Cash FlowOCF − Capex | $1.6M | $-977.3K |
| FCF MarginFCF / Revenue | 17.8% | -19.5% |
| Capex IntensityCapex / Revenue | 4.4% | 3.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | $-2.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $-812.5K | ||
| Q3 25 | $-3.7M | $-240.7K | ||
| Q2 25 | $-5.2M | $-704.2K | ||
| Q1 25 | $-5.1M | $-189.5K | ||
| Q4 24 | $4.0M | $-317.9K | ||
| Q3 24 | $4.1M | $167.4K | ||
| Q2 24 | $-3.6M | $289.8K | ||
| Q1 24 | — | $-704.1K |
| Q4 25 | $1.6M | $-977.3K | ||
| Q3 25 | $-4.2M | $-243.6K | ||
| Q2 25 | $-5.7M | $-705.7K | ||
| Q1 25 | $-5.4M | $-205.0K | ||
| Q4 24 | $3.6M | $-482.3K | ||
| Q3 24 | $4.0M | $157.4K | ||
| Q2 24 | $-3.8M | — | ||
| Q1 24 | — | $-708.7K |
| Q4 25 | 17.8% | -19.5% | ||
| Q3 25 | -23.7% | -5.2% | ||
| Q2 25 | -36.2% | -15.3% | ||
| Q1 25 | -53.0% | -4.3% | ||
| Q4 24 | 19.6% | -9.4% | ||
| Q3 24 | 22.4% | 3.5% | ||
| Q2 24 | -28.1% | — | ||
| Q1 24 | — | -16.2% |
| Q4 25 | 4.4% | 3.3% | ||
| Q3 25 | 2.8% | 0.1% | ||
| Q2 25 | 2.8% | 0.0% | ||
| Q1 25 | 3.0% | 0.3% | ||
| Q4 24 | 2.3% | 3.2% | ||
| Q3 24 | 0.5% | 0.2% | ||
| Q2 24 | 1.3% | 0.0% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | — | ||
| Q2 25 | -31.91× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.61× | -21.06× | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | 0.63× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
YCBD
| Sales Channel Directly To Consumer | $3.6M | 72% |
| Sales Channel Through Intermediary | $1.4M | 28% |
